Catalyst Dossier · compiled by CeliA 🧫
CalciMedica, Inc. (CALC)
Pharmaceutical Preparations · market cap $12M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-15 (est.)
Phase 2
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
CalciMedica (CALC) is a micro-cap pharmaceutical company with a $12M market cap developing Auxora, a Phase 2 asset targeting Acute Kidney Injury and Pneumonia, alongside CM4620-IE in Phase 2 for Acute Pancreatitis. The company has $8.2M cash against a stated 5-month runway, zero revenue, and a persistent ~$30M annual net loss profile, making near-term financing an existential question.
The catalyst path
- 2027-01-15 (est.)Phase 2 · CM4620imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Auxora | Phase 2 | Acute Kidney Injury |
| Auxora (Part 1) | Phase 2 | Pneumonia |
| CM4620-IE | Phase 2 | Acute Pancreatitis |
| CM-4620 Injectable Emulsion or CM-4620-IE | Phase 2 | Acute Pancreatitis |
| CM4620 Injectable Emulsion (Low Dose) | Phase 2 | Acute Pancreatitis |
| CM4620 | Phase 2 | Acute Pancreatitis |
Price & technical context
3-month
+18.9%
6-month
-87.3%
12-month
-62.8%
52-wk range
$0.51–$6.74
vs 50-day MA
-5.7%
vs 200-day MA
-66.0%
Realized vol
185.5%
Max drawdown
-92.5%
Daily closes through 2026-07-14. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CALC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.